[go: up one dir, main page]

WO1996033279A3 - Procede de clonage de repertoires, produits derives de ce dernier et utilisations desdits produits - Google Patents

Procede de clonage de repertoires, produits derives de ce dernier et utilisations desdits produits Download PDF

Info

Publication number
WO1996033279A3
WO1996033279A3 PCT/US1996/005114 US9605114W WO9633279A3 WO 1996033279 A3 WO1996033279 A3 WO 1996033279A3 US 9605114 W US9605114 W US 9605114W WO 9633279 A3 WO9633279 A3 WO 9633279A3
Authority
WO
WIPO (PCT)
Prior art keywords
products
cloning process
derived therefrom
repertoire cloning
products derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/005114
Other languages
English (en)
Other versions
WO1996033279A2 (fr
Inventor
Gregory F Okasinski
Dennis G Fry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to EP96910825A priority Critical patent/EP0821738A2/fr
Priority to JP8531818A priority patent/JPH11504208A/ja
Publication of WO1996033279A2 publication Critical patent/WO1996033279A2/fr
Publication of WO1996033279A3 publication Critical patent/WO1996033279A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Procédé de clonage de répertoires pour produire des anticorps monoclonaux. L'invention décrit également des procédés pour utiliser lesdits anticorps monoclonaux et des nécessaires les contenant.
PCT/US1996/005114 1995-04-21 1996-04-12 Procede de clonage de repertoires, produits derives de ce dernier et utilisations desdits produits Ceased WO1996033279A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96910825A EP0821738A2 (fr) 1995-04-21 1996-04-12 Procede de clonage de repertoires, produits derives de ce dernier et utilisations desdits produits
JP8531818A JPH11504208A (ja) 1995-04-21 1996-04-12 レパートリークローニング法、それから得られる産物及びその産物の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42679195A 1995-04-21 1995-04-21
US08/426,791 1995-04-21

Publications (2)

Publication Number Publication Date
WO1996033279A2 WO1996033279A2 (fr) 1996-10-24
WO1996033279A3 true WO1996033279A3 (fr) 1997-03-13

Family

ID=23692221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/005114 Ceased WO1996033279A2 (fr) 1995-04-21 1996-04-12 Procede de clonage de repertoires, produits derives de ce dernier et utilisations desdits produits

Country Status (4)

Country Link
EP (1) EP0821738A2 (fr)
JP (1) JPH11504208A (fr)
CA (1) CA2218651A1 (fr)
WO (1) WO1996033279A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446897A1 (fr) 2005-01-06 2012-05-02 Novo Nordisk A/S Traitements de combinaison anti-KIR et procédés
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (fr) * 1989-07-26 1991-02-21 City Of Hope Anticorps chimerique anti-antigene carcinoembryonique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (fr) * 1989-07-26 1991-02-21 City Of Hope Anticorps chimerique anti-antigene carcinoembryonique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
D. BURTON: "Human and mouse monoclonal antibodies by repertoire cloning.", TRENDS IN BIOTECHNOLOGY, vol. 9, no. 5, May 1991 (1991-05-01), CAMBRIDGE, GB, pages 169 - 175, XP000207982 *
I. MACLEAN ET AL.: "Production of recombinant Chlamydia trachomatis serovar D major outer membrane protein.", VACCINE, vol. 7, no. 2, April 1989 (1989-04-01), USA, pages 179 - 180, XP002024053 *
M. DUCHOSAL ET AL.: "Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries.", NATURE, vol. 355, no. 6357, 16 January 1992 (1992-01-16), LONDON, GB, pages 258 - 262, XP002024052 *
M. POSNER ET AL.: "The generation of hybridomas secreting human monoclonal antibodies reactive with type II collagen.", HYBRIDOMA, vol. 8, no. 2, April 1989 (1989-04-01), NEW YORK, NY, USA, pages 187 - 197, XP000616479 *
N. MCCARTHY-FRANCIS ET AL.: "Kappa-chain allotypes and isotypes in the rabbit: cDNA sequences of clones encoding b9 suggest an evolutionary pathway and possible role of the interdomain disulfide bond in quantitative allotype expression.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 81, no. 5, March 1984 (1984-03-01), WASHINGTON, DC, USA, pages 1794 - 1798, XP002024054 *
P. FISCHER ET AL.: "Human monoclonal antibodies derived by repertoire cloning from immunized hu-PBL-SCID mice.", IMMUNOBIOLOGY, vol. 183, no. 3-4, October 1991 (1991-10-01), STUTTGART, GERMANY, pages 292 - 293, XP000616502 *
W. NIEDBALA ET AL.: "In vitro sensitization for human monoclonal antibody production.", IMMUNOLOGY LETTERS, vol. 35, no. 2, February 1993 (1993-02-01), AMSTERDAM, NL, pages 93 - 100, XP000616470 *

Also Published As

Publication number Publication date
JPH11504208A (ja) 1999-04-20
EP0821738A2 (fr) 1998-02-04
CA2218651A1 (fr) 1996-10-24
WO1996033279A2 (fr) 1996-10-24

Similar Documents

Publication Publication Date Title
AU1432195A (en) Process for generating specific antibodies
CA2056102A1 (fr) Methode de production d'anticorps
CA2220461A1 (fr) Composes therapeutiques constitues d'anticorps anti-recepteurs fc
AU2910197A (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
AU4716296A (en) Process for producing thietanones
BR9609043A (pt) Método de preparar 3 haloalqui 1h pirazois
ZA964820B (en) Method for obtaining receptor angonist antibodies
AU5055593A (en) Antibodies specific for HIV
AU1241795A (en) Anti-egf-r/anti-cd3 bispecific monoclonal antibody, method for its production and its use
EP1881064A3 (fr) Anticorps monoclonaux HCV-anti-cýur
WO1998022510A3 (fr) Procedes de production d'anticorps monoclonaux de poulet
EP0831098A3 (fr) Produits intermédiaires et procédé pour la préparation d'olanzapine
HUP9900149A3 (en) Process for producing l-lysine by fermentation
ZA964757B (en) Process for preparing ferrierite.
WO1999065947A3 (fr) Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
AU6061896A (en) Method for waterproofing leather
AU8442391A (en) Corynebacteria integron, method of transformation of corynebacteria by said integron, and corynebacteria obtained
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
AU4221296A (en) Process for preparing an organoaluminoxy product
AU697864B2 (en) Guide ring for I.S. glass forming machine
EP0781846A3 (fr) Antigène de fusion de treponema palladium, essai d'anticorps anti-treponema palladium avec ces antigènes de fusion
WO1996033279A3 (fr) Procede de clonage de repertoires, produits derives de ce dernier et utilisations desdits produits
AU7074996A (en) Method for making cheesecake
AU698813B2 (en) Process for producing transglutaminase by microorganism
EP0613899A3 (fr) Dérivé de la cocaine, son conjugate de protéine, lignée cellulaire produisant un anticorps monoclonal, procédé de production de la lignée cellulaire et anticorps monoclonal.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2218651

Country of ref document: CA

Ref country code: CA

Ref document number: 2218651

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 531818

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996910825

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996910825

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996910825

Country of ref document: EP